Belantamab Mafodotin Combo Shows PFS Improvement in R/R Multiple Myeloma

被引：0
|
作者：
不详
机构：
来源：
ONCOLOGY-NEW YORK | 2024年 / 38卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：44
相关论文
共 50 条
  • [21] Adverse ocular events related to belantamab mafodotin for treatment of multiple myeloma
    Lent-Schochet, Daniella
    Mokhashi, Nikita
    Vidyasagar, Nitin
    Farooq, Asim
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2024, 65 (07)
  • [22] Multiple Myeloma Belantamab Mafodotin opens up New Treatment Perspective
    Sankawa, Yuri
    ACTA HAEMATOLOGICA, 2021, 144 (05) : 592 - 593
  • [23] Ocular Toxicity of Commercially Available Belantamab Mafodotin in Patients with Advanced Multiple Myeloma
    Abeykoon, Jithma P.
    Vaxman, Luliana
    Patel, Sanjay V.
    Kumar, Shaji
    Young, Kimberly S.
    Ailawadhi, Sikander
    Larsen, Jeremy T.
    Gonsalves, Wilson I.
    Kourelis, Taxiarchis
    Leung, Nelson
    Warsame, Rahma M.
    Hobbs, Miriam A.
    Fonder, Amie
    Hwa, Yi L.
    Bergsage, P. Leif
    Lacy, Martha Q.
    kumar, S. Vincent Raj
    Gertz, Morie A.
    Kapoor, Prashant
    BLOOD, 2021, 138
  • [24] Long-lasting effect of belantamab mafodotin in heavily pretreated multiple myeloma
    David Gil-Sierra, Manuel
    Del Pilar Briceno-Casado, Maria
    Javier Julia-Luna, Francisco
    Dolores Martinez-Moya, Maria
    INDIAN JOURNAL OF PHARMACOLOGY, 2022, 54 (05) : 373 - 376
  • [25] Safety and efficacy of belantamab mafodotin with pembrolizumab in patients with relapsed or refractory multiple myeloma
    Suvannasankha, Attaya
    Bahlis, Nizar
    Trudel, Suzanne
    Weisel, Katja
    Koenecke, Christian
    Oriol, Albert
    Voorhees, Peter M.
    Alonso, Aranzazu A.
    Callander, Natalie S.
    Mateos, Maria-Victoria
    Reddy, Nishitha
    Hakim, Shawn
    Lamacchia, John
    Patel, Nashita
    Williams, Danae
    Jewell, Roxanne. C.
    Zhou, Xiangdong
    Gupta, Ira
    Opalinska, Joanna
    Nooka, Ajay K.
    CANCER, 2024, 130 (15) : 2629 - 2641
  • [26] FDA Approval Summary: Belantamab Mafodotin for Patients with Relapsed or Refractory Multiple Myeloma
    Baines, Andrea C.
    Ershler, Rachel
    Kanapuru, Bindu
    Xu, Qing
    Shen, Guoxiang
    Li, Liang
    Ma, Lian
    Okusanya, Olanrewaju O.
    Simpson, Natalie E.
    Nguyen, Wanda
    Theoret, Marc R.
    Pazdur, Richard
    Gormley, Nicole J.
    CLINICAL CANCER RESEARCH, 2022, 28 (21) : 4629 - 4633
  • [27] Occurrence of corneal microcystoid alterations under administration of belantamab mafodotin for multiple myeloma
    Zimmermann, Julian
    Esser, E.
    Eter, N.
    Schuett, P.
    Uhlig, C. E.
    OPHTHALMOLOGIE, 2023, 120 (07): : 747 - 750
  • [28] The Antibody Drug Conjugate, Belantamab-Mafodotin, in the Treatment of Multiple Myeloma: A Comprehensive Review
    Diaz, Adrian Alfonso Almodovar
    Alouch, Samhar Samer
    Chawla, Yogesh
    Gonsalves, Wilson, I
    BLOOD AND LYMPHATIC CANCER-TARGETS AND THERAPY, 2024, 14 : 71 - 87
  • [29] Belantamab mafodotin, pomalidomide and dexamethasone in refractory multiple myeloma: a phase 1/2 trial
    Suzanne Trudel
    Arleigh McCurdy
    Martha L. Louzada
    Stephen Parkin
    Darrell White
    Michael P. Chu
    Rami Kotb
    Hira Mian
    Ibraheem Othman
    Jiandong Su
    Aniba Khan
    Engin Gul
    Donna Reece
    Nature Medicine, 2024, 30 : 543 - 551
  • [30] The clinical journey of belantamab mafodotin in relapsed or refractory multiple myeloma: lessons in drug development
    Mukhopadhyay, Pralay
    Abdullah, Hesham A.
    Opalinska, Joanna B.
    Paka, Prani
    Richards, Eric
    Weisel, Katja
    Trudel, Suzanne
    Mateos, Maria-Victoria
    Dimopoulos, Meletios Athanasios
    Lonial, Sagar
    BLOOD CANCER JOURNAL, 2025, 15 (01):
12345